Compare WNEB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | ARMP |
|---|---|---|
| Founded | 1853 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 295.5M |
| IPO Year | 2001 | 1996 |
| Metric | WNEB | ARMP |
|---|---|---|
| Price | $14.61 | $6.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $13.67 | ★ $15.00 |
| AVG Volume (30 Days) | 55.9K | ★ 169.4K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 33.93 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $44,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $61.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.57 | $2.14 |
| 52 Week High | $14.68 | $14.98 |
| Indicator | WNEB | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 67.33 | 35.73 |
| Support Level | $12.09 | $5.14 |
| Resistance Level | N/A | $6.60 |
| Average True Range (ATR) | 0.43 | 0.74 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 94.56 | 3.71 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.